November 2021 - CanadianCannabisWire

MondayNov 29, 2021 9:30 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Schedules November 29th for Q3 2021 Financials Release; November 30th for Earnings Discussion

RWB is set to release its Q3 financial results on November 29, 2021 A conference call will follow this release on November 30, 2021, at 5:00 PM ET to discuss these results, the company’s operations, upcoming events, and a Q&A session A replay of the call will be available for 90 days, starting three hours after the conclusion RWB is increasingly optimistic about its Q3 performance following growth in revenue from Q1 to Q2, along with strategic investments that would allow for Q3 growth Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) just announced that it will be releasing…

MondayNov 29, 2021 9:30 am

RYAH Group Inc. (CSE: RYAH) Releases Overview of UK Cannabis Market

Market analysts place high hopes on the potential of the United Kingdom market Growing demand from patients and patient families brought the country’s medical cannabis program to a tipping point RYAH is committed to providing valuable insight and transforming patient care through big data and artificial intelligence After three years of medical cannabis being legal in the United Kingdom, the country has a total of only three patients with a prescription in the entire public system, noted a recent blog from RYAH Group (CSE: RYAH). The article noted that many more patients receive cannabis-derived medications, including flower and cannabis oil,…

MondayNov 29, 2021 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs

InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trials The company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 million Following the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare cannabinoids, growing revenue, and expanding sales InMed has commenced Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders Preclinical data of INM-088, the company’s…

WednesdayNov 24, 2021 8:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications

Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension HYPER-H21-4 will build on successes witnessed in initial human hypertension studies The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, including dementia, diabetes, and rheumatoid disease Lexaria is committed to improving lives and lessening deaths through its patented DehydraTECH(TM) technology With a fully-funded research and development (“R&D”) budget, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed, efficacy, bioavailability, and brain absorption of…

TuesdayNov 23, 2021 8:30 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Adding to its Growing Retail Presence with Rapid Developments in Florida

Red White & Bloom Brands is building a multi-state operation in the cannabis and hemp industries through state subsidiaries focused on markets in Florida, Michigan, Illinois, Arizona and California The company is now rapidly building up its cultivation and retail operations in Florida, advancing from regulatory approval in the state last month to the startup of growing activity to supply existing and soon-to-open dispensaries in four cities from Miami to Daytona Beach and across to Spring Hill Florida is on the verge of a “massive medical marijuana boom” as the pain-conscious retirement community grows and residents’ attitudes overwhelmingly favor openness…

ThursdayNov 18, 2021 8:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes

Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets The 2022 program will continue to focus on the company’s patented DehydraTECH drug delivery platform Lexaria will also be conducting pharmacokinetic and efficacy modeling studies in animals to evaluate DehydraTECH’s overall efficiency In 2021, Lexaria Bioscience (NASDAQ: LEXX) raised approximately $15 million in funding. The money allowed for active work programs throughout the year while supporting significant advances in…

FridayNov 12, 2021 2:25 pm

Flora Growth Corp. (NASDAQ: FLGC) Expands Its Plant-Based CPG Market Reach, Celebrates International Medical Cannabis Certification

International cannabis cultivator, manufacturer, and distributor of plant-based lifestyle and wellness brands Flora Growth Corp. is steadily building a worldwide pipeline for downstream cannabis brands using its Colombian cultivation facilities and a growing list of trade partners Flora Growth recently announced multiple distribution and e-commerce marketplace agreements that will see its two leading skincare brands, MIND Naturals and Awe (Ô), distributed via GlossWire and Showfields The company also expects its Colombian on-site CBD extraction facility to come online as well as complete the first harvests of its high-THC psychoactive cultivars later in the month Flora Growth achieved Good Agricultural and…

FridayNov 12, 2021 1:25 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4

Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and it's most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings, as well as the HYPER-H21-3 study that is set to begin dosing in mid-November 2021 Lexaria’s goal is to pursue regulatory approval for its proprietary DehydraTECH-CBD for potential use as a treatment for high blood pressure Study protocols are being readied for submission to the IRB, and approval is expected by January 2022 Lexaria Bioscience (NASDAQ: LEXX) has, so far in 2021, embarked on several studies geared towards evaluating its proprietary DehydraTECH(TM) CBD for…

FridayNov 12, 2021 8:00 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Commences Installation of 30 Growing Pods, Produces First Batch of Chocolates at New Sanderson Production Facility

Red White & Bloom has officially entered Phase 2 of an aggressive three-phase expansion plan in Florida Phase 2 involves the installation and commissioning of 30 customized, self-contained growing pods RWB recently received OMMU approval for the first five pods that it subsequently installed and commissioned The company, through its Red White & Bloom Florida LLC subsidiary, produced the first batch of chocolates from the new Sanderson production facility, making substantial progress since launching the greenhouse facility in Apopka in late September Following the early October completion of phase one of a three-phase development strategy that captures Red White &…

WednesdayNov 10, 2021 12:05 pm

InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid

InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative disease and potentially enhance the neuronal function With neurogenerative diseases affecting millions worldwide and the cost of treating patients expected to rise in the future, finding treatments and cures is a matter of increasing urgency InMed’s patent application is a promising start, expanding the company’s patent portfolio, which currently includes twelve patent families InMed Pharmaceuticals (NASDAQ: INM), a global leader in the manufacturing and pharmaceutical development of rare cannabinoids, recently filed a Patent Cooperation Treaty (“PCT”) application, titled…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 512.354.7000

Month: November 2021